Belgian Media Stock News

UCB (ENXTBR:UCB) received FDA approval for KYGEVVI, marking a major step in rare disease treatment. KYGEVVI is the first approved therapy for TK2d, a life-threatening mitochondrial disorder with very limited options. See our latest analysis for UCB. Following the FDA approval for KYGEVVI, UCB's momentum has been building. The share price has climbed nearly 20% year-to-date. After some short-term volatility, the stock's 1-year total shareholder return stands at an impressive 26%. Those who...

Syensqo reported third quarter 2025 earnings, revealing sales of €1.56 billion and net income of €39 million, compared to a third quarter net loss in 2024, despite a year-on-year decline in revenue for both the quarter and nine months ending September 30. The company’s rebound to profitability in the third quarter, following a loss a year earlier, underscores a shift in its performance trend even amid lower sales. We’ll assess how Syensqo’s return to quarterly profit, despite weaker sales,...

UCB announced that KYGEVVI, a combination therapy for thymidine kinase 2 deficiency (TK2d), has received approval from the U.S. FDA, making it the first and only approved treatment for this ultra-rare, life-threatening mitochondrial disorder in both adults and pediatric patients with symptom onset before age 12. This approval provides UCB with entry into a new therapeutic area with high unmet need, and comes with a Rare Pediatric Disease Priority Review Voucher from the FDA, highlighting...

Lotus Bakeries was recently added to the Euronext 150 Index, highlighting its growing profile among Europe’s largest listed companies. This milestone can influence share demand as index-tracking funds and institutional investors may adjust holdings to include the company. We’ll now explore how inclusion in a major index could impact Lotus Bakeries’ investment narrative and future institutional interest. AI is about to change healthcare. These 32 stocks are working on everything from early...

This week we saw the Banqup Group SA ( EBR:BANQ ) share price climb by 11%. But that doesn't change the fact that the...

Anheuser-Busch InBev announced a US$6 billion share repurchase program and released its third quarter 2025 earnings, reporting sales of US$15.13 billion and net income of US$1.05 billion for the quarter ended September 30, 2025. The board also approved an interim dividend, renewed a key services framework with its Asia-Pacific subsidiary, and disclosed the upcoming departure of its longstanding Chief People Officer, marking a period of significant corporate actions. We'll explore how the...

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Key Insights Given the large stake in the stock by institutions, ageas' stock price might be vulnerable to their...

Key Insights The considerable ownership by sovereign wealth funds in bpost/SA indicates that they collectively have a...

Wondering if argenx is really worth its soaring share price? You are not alone, especially as buzz grows around how this stock stacks up against market expectations. argenx has delivered an impressive 30.8% return over the past year and is up 18.4% year-to-date, drawing fresh attention from growth-focused investors. Fueling recent price moves, the company has been in the spotlight due to positive new drug developments and regulatory wins that reinforce the long-term growth story behind the...

As the European market navigates a mixed landscape, with the STOXX Europe 600 Index recently pulling back after reaching new highs and interest rate expectations from the ECB remaining steady, investors are increasingly focused on identifying opportunities among undervalued stocks. In such an environment, a good stock is often characterized by its potential to trade below its estimated intrinsic value, offering room for appreciation as market conditions evolve.

Key Insights The considerable ownership by retail investors in Financière de Tubize indicates that they collectively...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'll...

Syensqo (ENXTBR:SYENS) shares moved modestly today, catching the eye of investors who are watching for shifts in valuation. The stock’s recent performance offers an interesting angle for those tracking the materials sector. See our latest analysis for Syensqo. Syensqo’s share price has shown some resilience lately, notching a 5.9% gain over the past month and a modest 1-year total shareholder return of 0.6%. While momentum has been somewhat uneven, today’s movement suggests that investors are...

Melexis NV reported its third quarter 2025 results, showing sales of €215.29 million and net income of €27.53 million, both significantly lower than the same period a year ago. The contraction in sales and profit indicates the company may be encountering operational or market challenges over the year so far. We’ll examine how reduced earnings for the quarter are influencing Melexis’ investment narrative and outlook for operational momentum. The end of cancer? These 29 emerging AI stocks are...

DEME Group (ENXTBR:DEME) has won Brazil’s inaugural auction for a port access channel concession, in partnership with FTS Participacoes Societarias. This 25-year contract covers operations and expansion at the vital Port of Parana. See our latest analysis for DEME Group. DEME Group’s announcement of the major Brazilian port concession appears to have reignited market attention, with a strong 6.6% share price return over the past month after a mixed year. While year-to-date returns remain...

Proximus PLC's ( EBR:PROX ) price-to-earnings (or "P/E") ratio of 4.2x might make it look like a strong buy right now...

Anheuser-Busch InBev (ENXTBR:ABI) posted a net profit margin of 12.2% for the most recent period, a jump from last year’s 9.9%. Over the past five years, the company has averaged 24.5% annual earnings growth, with current-year earnings up 20%. Although this is not as rapid as previous years, it is still growing. With analysts forecasting another 10.03% per year in earnings growth and the stock trading well below consensus fair value estimates, investors are likely to see the current...

argenx (ENXTBR:ARGX) has achieved a notable turnaround to profitability over the past year, posting high-quality earnings and sustaining a five-year annual earnings growth rate of 52.7%. Looking ahead, consensus forecasts point to annual earnings growth of 28%, outpacing the Belgian market’s 15.6% projection, while revenue is also expected to rise by 18.5% per year compared to an 8.4% market average. Investors are weighing these strong growth figures and recent profitability against...

Aedifica announced in late October that it has raised its 2025 earnings guidance and reported solid nine-month results, with sales reaching €271.79 million and net income of €194.12 million. A key highlight is the 3.1% like-for-like rental income growth, reflecting improved operational momentum alongside continued asset rotation and new investment initiatives. We'll explore how the uplifted earnings forecast reinforces Aedifica's investment narrative and signals continued operating momentum...

Cenergy Holdings (ENXTBR:CENER) has quietly posted some eye-catching returns over the past year, with shares climbing more than 70%. This strong momentum puts the stock in focus for investors who want to understand what is driving its performance. See our latest analysis for Cenergy Holdings. Cenergy Holdings’ 71% total shareholder return over the past year stands out against a backdrop of accelerating momentum. The company has also seen a 36.7% share price return in the last 90 days and...

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...

Aedifica (ENXTBR:AED) posted a net profit margin of 62.1%, doubling last year’s margin of 31.1%. EPS growth soared by 115.1% as the company rebounded from a 5-year annual decline of 10.7%. Revenue is forecast to grow 3% annually, below the Belgian market's 8.4%, but earnings are projected to climb 18.8% per year, outpacing the market's 15.6% rate. Positive investor sentiment is likely to focus on the strong momentum in profitability and attractive valuation metrics, even as financial...